← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS › IRRIGATING SOLUTIONS › Salt solutions
combinations
B05CB10
Forms & Strengths
- Inj: tranexamic acid 100mg/ml + epsilon-aminocaproic acid 50mg/ml
- Inj: tranexamic acid 1000mg/10ml + epsilon-aminocaproic acid 250mg/10ml
- Lyophilized powder for inj: tranexamic acid 1000mg + epsilon-aminocaproic acid 250mg
Adult Dosing
- Adult dosing: 1-2g of tranexamic acid + 250-500mg of epsilon-aminocaproic acid IV q6h
- For hemophilia: 100mg/kg of tranexamic acid + 25mg/kg of epsilon-aminocaproic acid IV q6h
- For hereditary angioedema: 1-2g of tranexamic acid + 250-500mg of epsilon-aminocaproic acid IV q6h
Pediatric Dosing
- Pediatric dosing: 20-40mg/kg of tranexamic acid + 5-10mg/kg of epsilon-aminocaproic acid IV q6h
- For hemophilia: 50-100mg/kg of tranexamic acid + 12.5-25mg/kg of epsilon-aminocaproic acid IV q6h
- For hereditary angioedema: 20-40mg/kg of tranexamic acid + 5-10mg/kg of epsilon-aminocaproic acid IV q6h
Indications
- Hemophilia
- Hereditary angioedema
- Coagulopathy
- Bleeding disorders
- Prophylaxis of bleeding in surgical procedures
Mechanism of Action
- Tranexamic acid: inhibits plasminogen activation and fibrinolysis
- Epsilon-aminocaproic acid: inhibits plasminogen activation and fibrinolysis
- Inhibition of fibrinolysis reduces bleeding
Contraindications
- Hypersensitivity to tranexamic acid or epsilon-aminocaproic acid
- Acute promyelocytic leukemia
- Subarachnoid hemorrhage
- Diabetic retinopathy
- History of thromboembolic events
Adverse Reactions
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Headache
- Dizziness
- Thromboembolic events
Drug Interactions
- Concomitant use with anticoagulants may increase risk of bleeding
- Concomitant use with antiplatelet agents may increase risk of bleeding
- Concomitant use with tetracyclines may increase risk of thromboembolic events
Curated Content: Needs Vetting Before Put to Clinical Use